ACHN Achillion Pharmaceuticals Inc.

6.15
-0.02  -0%
Previous Close 6.17
Open 6.19
Price To Book 3.97
Market Cap 861,563,629
Shares 140,091,647
Volume 1,182,181
Short Ratio
Av. Daily Volume 3,566,279
Stock charts supplied by TradingView

NewsSee all news

  1. European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor

    BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  2. Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

    BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  3. Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2

  4. Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting

    BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  5. Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc.

    NEW YORK, Nov. 4, 2019 /PRNewswire/ -- Achillion Pharmaceuticals, Inc. (ACHN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of ACHN to Alexion

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 completion due 2020.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 presentation at ASH December 9, 2019 at 6pm ET.
Danicopan (ACH-4471)
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
Phase 2 trial planned to commence 1H 2020.
ACH-5228
Paroxysmal nocturnal hemoglobinuria (PNH)

Latest News

  1. European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor

    BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  2. Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

    BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  3. Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2

  4. Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting

    BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  5. Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc.

    NEW YORK, Nov. 4, 2019 /PRNewswire/ -- Achillion Pharmaceuticals, Inc. (ACHN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of ACHN to Alexion

  6. Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  7. Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

    – Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.

  8. Achillion to Present at the Baird 2019 Global Healthcare Conference

    BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by